# Phase III Randomized, Double-Blind, Placebo-Controlled Study of Intravenous Immune Globulin for Multiple Sclerosis

> **NCT00004744** · PHASE3 · COMPLETED · sponsor: **National Institute of Neurological Disorders and Stroke (NINDS)** · enrollment: 76 (—)

## Conditions studied

- Multiple Sclerosis

## Interventions

- **DRUG:** immune globulin

## Key facts

- **NCT ID:** NCT00004744
- **Lead sponsor:** National Institute of Neurological Disorders and Stroke (NINDS)
- **Sponsor class:** NIH
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1993-02
- **Primary completion:** 1998-09
- **Final completion:** —
- **Target enrollment:** 76 (—)
- **Last updated:** 2008-09-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00004744

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00004744, "Phase III Randomized, Double-Blind, Placebo-Controlled Study of Intravenous Immune Globulin for Multiple Sclerosis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00004744. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*